U.S. markets closed
  • S&P Futures

    4,125.75
    +18.75 (+0.46%)
     
  • Dow Futures

    34,061.00
    +123.00 (+0.36%)
     
  • Nasdaq Futures

    13,184.00
    +83.75 (+0.64%)
     
  • Russell 2000 Futures

    2,178.00
    +9.40 (+0.43%)
     
  • Crude Oil

    63.62
    -0.20 (-0.31%)
     
  • Gold

    1,821.90
    -2.10 (-0.12%)
     
  • Silver

    27.04
    -0.02 (-0.07%)
     
  • EUR/USD

    1.2089
    +0.0004 (+0.04%)
     
  • 10-Yr Bond

    1.6680
    -0.0270 (-1.59%)
     
  • Vix

    23.13
    -4.46 (-16.17%)
     
  • GBP/USD

    1.4045
    -0.0007 (-0.05%)
     
  • USD/JPY

    109.5500
    +0.1160 (+0.11%)
     
  • BTC-USD

    49,296.11
    -738.06 (-1.48%)
     
  • CMC Crypto 200

    1,352.60
    -35.31 (-2.54%)
     
  • FTSE 100

    6,963.33
    -41.30 (-0.59%)
     
  • Nikkei 225

    27,987.15
    +539.14 (+1.96%)
     

Passage Bio to Participate in Upcoming April Investor Conferences

  • Oops!
    Something went wrong.
    Please try again later.
Passage Bio
·2 min read
  • Oops!
    Something went wrong.
    Please try again later.

PHILADELPHIA, March 25, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders, today announced that management will participate in three upcoming virtual investor conferences in April:

Guggenheim Healthcare Talks | 2021 Genomic Medicines & Rare Disease
Format: Panel
Date: Thursday, April 1, 2021
Time: 12:00 p.m. ET

Needham Healthcare Conference
Format: Presentation
Date: Tuesday, April 13, 2021
Time: 08:45 a.m. ET

Chardan 4th Annual Manufacturing Summit
Format: Fireside chat
Date: Monday, April 26, 2021
Time: 11:15 a.m. ET

A live webcast of the events will be available on the Investors & Media section of Passage Bio’s website at investors.passagebio.com. A replay of the presentation and fireside chat will be available for 30 days following the events.

About Passage Bio
At Passage Bio (Nasdaq: PASG), we are on a mission to provide life-transforming gene therapies for patients with rare, monogenic CNS diseases that replace their suffering with boundless possibility, all while building lasting relationships with the communities we serve. Based in Philadelphia, PA, our company has established a strategic collaboration and licensing agreement with the renowned University of Pennsylvania’s Gene Therapy Program to conduct our discovery and IND-enabling preclinical work. This provides our team with enhanced access to a broad portfolio of gene therapy candidates and future gene therapy innovations that we then pair with our deep clinical, regulatory, manufacturing and commercial expertise to rapidly advance our robust pipeline of optimized gene therapies into clinical testing. As we work with speed and tenacity, we are always mindful of patients who may be able to benefit from our therapies. More information is available at www.passagebio.com.

For further information, please contact:

Investors:
Stuart Henderson
Passage Bio
267.866.0114
shenderson@passagebio.com

Media:
Gwen Fisher
Passage Bio
215.407.1548
gfisher@passagebio.com